Strong Argenx stock trades close to 52-week high as Q2 2026 profits beat expectations
Published on 08/26/2026 at 08:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Argenx (ISIN NL0010832176) stock has been trading close to its 52-week high in August 2026 after the company reported strong Q2 2026 results with robust revenue growth and a profit margin above 31 percent, indicating a profitable position in the biotech sector. A recent Nasdaq quote as of August 24, 2026 showed the shares at $1,012.14, down 2.66 percent intraday but still within a narrow band of their 52-week high around $1,058.69, underscoring how investors are reacting to the latest earnings data.
Q2 2026 earnings beat and profitability
Recent earnings data summarizing Argenx's latest quarter highlight that the company generated $1.51 billion in revenue in Q2 fiscal 2026, supported by continued demand for its autoimmune therapies. The same overview reports that Argenx earned $472 million in the quarter, which translates into a profit margin of 31.16 percent for Q2 fiscal 2026, indicating that the company converted nearly one-third of its revenue into profit in that period.
Additional analyst-oriented coverage of the latest results notes that Argenx delivered $1.54 billion in revenue in its most recent quarter compared with a consensus estimate of $1.45 billion, representing a positive revenue surprise of $90 million. The same source indicates that earnings per share reached $7.32 in the quarter against an anticipated $5.86, implying an earnings beat of $1.46 per share and reinforcing the view that the company outperformed expectations on both the top and bottom line.
Share price, 52-week high, and valuation context
Market data for Argenx stock as of August 24, 2026 show a Nasdaq quote of $1,012.14 at 3:40 p.m. ET, which reflected a daily decline of 2.66 percent during that session but left the shares close to their recent highs. The same set of market information points to a 52-week high of roughly $1,058.69, which means the stock was trading less than 5 percent below its peak level over the past year during that August 24, 2026 session.
This proximity to the 52-week high after a modest intraday pullback suggests that investors have largely maintained confidence in the Argenx story following the Q2 2026 results. The combination of revenue growth, a profit margin above 31 percent, and earnings per share that exceeded expectations provides a tangible fundamental backdrop for the elevated valuation, especially in a biotech landscape where many peers are still loss-making or only marginally profitable.
Product and pipeline focus on autoimmune diseases
Argenx has built its business around antibody-based therapies targeting autoimmune diseases, with its lead products and clinical pipeline focusing on conditions where patients currently have limited treatment options. The company's commercial portfolio and ongoing trials are designed to deepen its presence in autoimmune indications while exploring new opportunities based on its antibody-engineering platform. This strategy aligns with the revenue and earnings profile seen in Q2 2026, where sales from its key therapies played a central role in driving the $1.51 billion revenue figure and the 31.16 percent profit margin.
Stock level and recent trading reference
For investors tracking the latest trading levels, Argenx stock most recently showed a Nasdaq quote of $1,012.14 as of August 24, 2026 at 3:40 p.m. ET, placing the shares within a few percentage points of their 52-week high near $1,058.69. This positioning, combined with the Q2 2026 revenue of $1.51 billion and quarterly earnings of $472 million, frames the stock as one where current profitability and growth are already reflected in the market price.
Fact box
Company: Argenx SE
ISIN: NL0010832176
Ticker: ARGX
Exchange: Nasdaq
Price (as of August 24, 2026, 3:40 p.m. ET): $1,012.14 USD
Sector / Industry: Biotechnology focused on autoimmune disease therapies
